{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:40:52Z","timestamp":1790764852462,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"am","delay-in-days":648,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.smim.2022.101634","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T10:42:49Z","timestamp":1657276969000},"page":"101634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases"],"prefix":"10.1016","volume":"60","author":[{"given":"Marie-Sophie","family":"Meuleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Grunenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Chauvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.smim.2022.101634_bib1","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.smim.2022.101634_bib2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.smim.2022.101634_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy \u2014 understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"issue":"6","key":"10.1016\/j.smim.2022.101634_bib4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.smim.2022.101634_bib5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.smim.2022.101634_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ki.2013.340","article-title":"Toward a working definition of C3 glomerulopathy by immunofluorescence","volume":"85","author":"Hou","year":"2014","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.smim.2022.101634_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.smim.2022.101634_bib8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 Glomerulopathy: ten years\u2019 experience at mayo clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clin. Proc."},{"issue":"4","key":"10.1016\/j.smim.2022.101634_bib9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.smim.2022.101634_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 Glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"CJASN"},{"issue":"4","key":"10.1016\/j.smim.2022.101634_bib11","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.smim.2022.101634_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2022.101634_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.smim.2022.101634_bib14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.smim.2022.101634_bib15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","article-title":"Eculizumab for treatment of rapidly progressive C3 glomerulopathy","volume":"65","author":"Le Quintrec","year":"2015","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.smim.2022.101634_bib16","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.smim.2022.101634_bib17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.ajkd.2018.09.002","article-title":"Kidney transplantation in C3 glomerulopathy: a case series","volume":"73","author":"Regunathan-Shenk","year":"2019","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.smim.2022.101634_bib18","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1681\/ASN.2013070715","article-title":"Clinical findings, pathology, and outcomes of C3GN after kidney transplantation","volume":"25","author":"Zand","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.smim.2022.101634_bib19","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.smim.2022.101634_bib20","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1681\/ASN.2016030343","article-title":"Anti-Factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN","volume":"28","author":"Marinozzi","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.smim.2022.101634_bib21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10875-016-0290-5","article-title":"Testing the activity of complement convertases in serum\/plasma for diagnosis of C4NeF-mediated C3 glomerulonephritis","volume":"36","author":"Blom","year":"2016","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.smim.2022.101634_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.smim.2022.101634_bib23","doi-asserted-by":"crossref","unstructured":"Caravaca-Font\u00e1n F., Lucientes L., Serra N., Cavero T., Rodado R., Ramos N., et al. C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies. Nephrol Dial Transplant. 2021 Oct 22;gfab302.","DOI":"10.1093\/ndt\/gfab302"},{"key":"10.1016\/j.smim.2022.101634_bib24","unstructured":"Wong E.K.S., Marchbank K.J., Lomax-Browne H., Pappworth I.Y., Denton H., Cooke K., et al. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes. Clin J Am Soc Nephrol. 2021 Nov;16(11):1639\u201351."},{"issue":"11","key":"10.1016\/j.smim.2022.101634_bib25","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.2215\/CJN.01820214","article-title":"Defining the complement biomarker profile of C3 glomerulopathy","volume":"9","author":"Zhang","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.smim.2022.101634_bib26","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.smim.2022.101634_bib27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ki.2012.212","article-title":"C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.smim.2022.101634_bib28","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/ki.2008.657","article-title":"Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway","volume":"75","author":"Sethi","year":"2009","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.smim.2022.101634_bib29","first-page":"459","article-title":"Characterization of C3 in C3 glomerulopathy","volume":"32","author":"Sethi","year":"2017","journal-title":"Nephrol. Dial. Transpl."},{"issue":"10","key":"10.1016\/j.smim.2022.101634_bib30","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ekir.2019.06.008","article-title":"Glomerular complement factor H-related protein 5 (FHR5) is highly prevalent in c3 glomerulopathy and associated with renal impairment","volume":"4","author":"Medjeral-Thomas","year":"2019","journal-title":"Kidney Int Rep."},{"issue":"2","key":"10.1016\/j.smim.2022.101634_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2215\/CJN.07900811","article-title":"Causes of alternative pathway dysregulation in dense deposit disease","volume":"7","author":"Zhang","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.smim.2022.101634_bib32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ng912","article-title":"Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H","volume":"31","author":"Pickering","year":"2002","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.smim.2022.101634_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1681\/ASN.2020050698","article-title":"Humanized C3 mouse: a novel accelerated model of C3 glomerulopathy","volume":"32","author":"Devalaraja-Narashimha","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"issue":"25","key":"10.1016\/j.smim.2022.101634_bib34","doi-asserted-by":"crossref","first-page":"11490","DOI":"10.1073\/pnas.92.25.11490","article-title":"Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity","volume":"92","author":"Wessels","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.smim.2022.101634_bib35","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.2215\/CJN.01820214","article-title":"Defining the complement biomarker profile of C3 glomerulopathy","volume":"9","author":"Zhang","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"25","key":"10.1016\/j.smim.2022.101634_bib36","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.0601094103","article-title":"Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice","volume":"103","author":"Pickering","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"3","key":"10.1016\/j.smim.2022.101634_bib37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.smim.2022.101634_bib38","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1681\/ASN.2011121186","article-title":"Pathology after eculizumab in dense deposit disease and C3 GN","volume":"23","author":"Herlitz","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.smim.2022.101634_bib39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","volume":"72","author":"Le Quintrec","year":"2018","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"10.1016\/j.smim.2022.101634_bib40","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood.2020005959","article-title":"Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity","volume":"137","author":"Mannes","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.smim.2022.101634_bib41","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3389\/fimmu.2020.01875","article-title":"The complement C3a and C3a receptor pathway in kidney diseases","volume":"11","author":"Gao","year":"2020","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.smim.2022.101634_bib42","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ki.2011.158","article-title":"Distinct roles for C3a and C5a in complement-induced tubulointerstitial injury","volume":"80","author":"Bao","year":"2011","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.smim.2022.101634_bib43","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1681\/ASN.2008040434","article-title":"C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy","volume":"20","author":"Tang","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.smim.2022.101634_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.smim.2022.101634_bib45","doi-asserted-by":"crossref","first-page":"884","DOI":"10.4049\/jimmunol.157.2.884","article-title":"Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library","volume":"157","author":"Sahu","year":"1996","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.smim.2022.101634_bib46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0161-5890(02)00212-2","article-title":"Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3","volume":"39","author":"Sahu","year":"2003","journal-title":"Mol. Immunol."},{"issue":"40","key":"10.1016\/j.smim.2022.101634_bib47","doi-asserted-by":"crossref","first-page":"29241","DOI":"10.1074\/jbc.M704587200","article-title":"Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition","volume":"282","author":"Janssen","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.smim.2022.101634_bib48","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/blood.V92.5.1661","article-title":"Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation","volume":"92","author":"Nilsson","year":"1998","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.smim.2022.101634_bib49","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.imbio.2015.04.001","article-title":"Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy","volume":"220","author":"Zhang","year":"2015","journal-title":"Immunobiology"},{"issue":"4","key":"10.1016\/j.smim.2022.101634_bib50","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int."},{"issue":"5247","key":"10.1016\/j.smim.2022.101634_bib51","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1126\/science.271.5247.348","article-title":"C3d of complement as a molecular adjuvant: bridging innate and acquired immunity","volume":"271","author":"Dempsey","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.smim.2022.101634_bib52","article-title":"Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort","author":"Michels","year":"2021","journal-title":"Pedia Nephrol."},{"issue":"16","key":"10.1016\/j.smim.2022.101634_bib53","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532322000513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532322000513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:23:21Z","timestamp":1760916201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532322000513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":53,"alternative-id":["S1044532322000513"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2022.101634","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2022.101634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101634"}}